Arrowhead Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARWR and other ETFs, options, and stocks.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.

CEO

Christopher Richard Anzalone

CEOChristopher Richard Anzalone

Employees

609

Employees609

Headquarters

Pasadena, California

HeadquartersPasadena, California

Founded

1989

Founded1989

Employees

609

Employees609

ARWR Key Statistics

Market cap

4.04B

Market cap4.04B

Price-Earnings ratio

-22.69

Price-Earnings ratio-22.69

Dividend yield

—

Dividend yield—

Average volume

3.39M

Average volume3.39M

High today

$29.38

High today$29.38

Low today

$28.48

Low today$28.48

Open price

$28.78

Open price$28.78

Volume

1.08M

Volume1.08M

52 Week high

$31.13

52 Week high$31.13

52 Week low

$9.57

52 Week low$9.57

ARWR News

TipRanks 1d

Arrowhead Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Arrowhead Pharmaceuticals. The associated price target remains the same with $80...

Simply Wall St 2d

Patent Dispute Over Plozasiran Might Change The Case For Investing In Arrowhead Pharmaceuticals

Earlier this month, Ionis Pharmaceuticals filed a patent infringement lawsuit against Arrowhead Pharmaceuticals in California alleging infringement related to A...

TipRanks 4d

Arrowhead Pharmaceuticals Faces Patent Lawsuit from Ionis

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Analyst ratings

71%

of 14 ratings

Buy

71.4%

Hold

28.6%

Sell

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.